KR100893977B1 - 이소티아졸 유도체의 제조 방법 - Google Patents

이소티아졸 유도체의 제조 방법 Download PDF

Info

Publication number
KR100893977B1
KR100893977B1 KR1020077004371A KR20077004371A KR100893977B1 KR 100893977 B1 KR100893977 B1 KR 100893977B1 KR 1020077004371 A KR1020077004371 A KR 1020077004371A KR 20077004371 A KR20077004371 A KR 20077004371A KR 100893977 B1 KR100893977 B1 KR 100893977B1
Authority
KR
South Korea
Prior art keywords
benzyloxy
carboxylic acid
ureido
isothiazole
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077004371A
Other languages
English (en)
Korean (ko)
Other versions
KR20070070158A (ko
Inventor
데이비드 비 다몬
브라이언 피 존스
Original Assignee
화이자 프로덕츠 인코포레이티드
오에스아이 파마슈티컬스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 프로덕츠 인코포레이티드, 오에스아이 파마슈티컬스, 인코포레이티드 filed Critical 화이자 프로덕츠 인코포레이티드
Publication of KR20070070158A publication Critical patent/KR20070070158A/ko
Application granted granted Critical
Publication of KR100893977B1 publication Critical patent/KR100893977B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1020077004371A 2004-08-26 2005-08-02 이소티아졸 유도체의 제조 방법 Expired - Fee Related KR100893977B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60454204P 2004-08-26 2004-08-26
US60/604,542 2004-08-26

Publications (2)

Publication Number Publication Date
KR20070070158A KR20070070158A (ko) 2007-07-03
KR100893977B1 true KR100893977B1 (ko) 2009-04-20

Family

ID=36000502

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077004371A Expired - Fee Related KR100893977B1 (ko) 2004-08-26 2005-08-02 이소티아졸 유도체의 제조 방법

Country Status (21)

Country Link
US (2) US8884025B2 (enExample)
EP (1) EP1784183B1 (enExample)
JP (2) JP5100390B2 (enExample)
KR (1) KR100893977B1 (enExample)
CN (1) CN101043888B (enExample)
AR (1) AR050613A1 (enExample)
AT (1) ATE542533T1 (enExample)
AU (1) AU2005280451B2 (enExample)
BR (1) BRPI0514667A (enExample)
CA (1) CA2578023C (enExample)
DK (1) DK1784183T3 (enExample)
ES (1) ES2378994T3 (enExample)
IL (1) IL181063A0 (enExample)
MX (1) MX2007002246A (enExample)
NO (1) NO20071319L (enExample)
PL (1) PL1784183T3 (enExample)
PT (1) PT1784183E (enExample)
RU (1) RU2349588C2 (enExample)
TW (1) TWI361688B (enExample)
WO (1) WO2006026034A2 (enExample)
ZA (1) ZA200701016B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101043888B (zh) 2004-08-26 2010-08-11 辉瑞有限公司 制备异噻唑衍生物的方法
US8969583B2 (en) 2011-12-28 2015-03-03 Allergan, Inc. 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors
CN103833665B (zh) * 2014-02-24 2015-09-23 杰达维（上海）医药科技发展有限公司 一种新的合成异噻唑的方法
US9353093B2 (en) 2014-10-07 2016-05-31 Allergan, Inc. Indole-1-carboxamides as kinase inhibitors
US9403803B2 (en) 2014-10-08 2016-08-02 Allergan, Inc. Indole-3-carboxamides as kinase inhibitors
US9359336B2 (en) 2014-10-09 2016-06-07 Allergan, Inc. Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
US9371314B2 (en) 2014-10-09 2016-06-21 Allergan, Inc. Pyridyl benzothiophenes as kinase inhibitors
KR20250121146A (ko) * 2022-12-28 2025-08-11 비양 테라퓨틱스 컴퍼니 리미티드 단백질 티로신 키나제 억제제 및 이의 의약적 용도
WO2026002126A1 (zh) * 2024-06-27 2026-01-02 苏州必扬医药科技有限公司 一种蛋白酪氨酸激酶抑制剂及其眼用制剂
WO2026002137A1 (zh) * 2024-06-27 2026-01-02 苏州必扬医药科技有限公司 一种蛋白酪氨酸激酶抑制剂游离碱的晶型

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235764B1 (en) 1998-06-04 2001-05-22 Pfizer Inc. Isothiazole derivatives useful as anticancer agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2408234A1 (de) * 1974-02-21 1975-09-04 Celamerck Gmbh & Co Kg Isothiazolylharnstoffe
US4059433A (en) * 1976-06-18 1977-11-22 Fmc Corporation 3-Alkoxyisothiazole derivatives as herbicides
IL72093A0 (en) * 1983-06-20 1984-10-31 Lilly Co Eli N'-substituted(3-alkyl-5-isothiazolyl)urea derivatives
HN2000000051A (es) * 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
GB0010188D0 (en) * 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
CA2493701A1 (en) * 2002-07-25 2004-02-05 Pfizer Products Inc. Isothiazole derivatives useful as anticancer agents
US20060035954A1 (en) * 2004-08-11 2006-02-16 Sharma Padam N Ammonolysis process for the preparation of intermediates for DPP IV inhibitors
CN101043888B (zh) 2004-08-26 2010-08-11 辉瑞有限公司 制备异噻唑衍生物的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235764B1 (en) 1998-06-04 2001-05-22 Pfizer Inc. Isothiazole derivatives useful as anticancer agents
KR20010052516A (ko) * 1998-06-04 2001-06-25 데이비드 존 우드 항암제로 유용한 이소티아졸 유도체
US6548526B2 (en) 1998-06-04 2003-04-15 Pfizer Inc Isothiazole derivatives useful as anticancer agents

Also Published As

Publication number Publication date
JP2012153705A (ja) 2012-08-16
CN101043888A (zh) 2007-09-26
BRPI0514667A (pt) 2008-06-17
MX2007002246A (es) 2007-04-20
ATE542533T1 (de) 2012-02-15
CA2578023C (en) 2012-05-15
EP1784183A4 (en) 2009-12-09
KR20070070158A (ko) 2007-07-03
JP2008510841A (ja) 2008-04-10
US20090023924A1 (en) 2009-01-22
WO2006026034A2 (en) 2006-03-09
HK1111359A1 (en) 2008-08-08
US8884025B2 (en) 2014-11-11
JP5498524B2 (ja) 2014-05-21
EP1784183B1 (en) 2012-01-25
AU2005280451A1 (en) 2006-03-09
RU2007106847A (ru) 2008-08-27
NO20071319L (no) 2007-05-29
JP5100390B2 (ja) 2012-12-19
AR050613A1 (es) 2006-11-08
DK1784183T3 (da) 2012-04-02
PT1784183E (pt) 2012-03-09
PL1784183T3 (pl) 2012-07-31
AU2005280451B2 (en) 2009-02-05
US9371298B2 (en) 2016-06-21
ES2378994T3 (es) 2012-04-19
TW200621241A (en) 2006-07-01
CN101043888B (zh) 2010-08-11
IL181063A0 (en) 2007-07-04
TWI361688B (en) 2012-04-11
WO2006026034A3 (en) 2006-06-29
ZA200701016B (en) 2008-05-28
EP1784183A2 (en) 2007-05-16
RU2349588C2 (ru) 2009-03-20
CA2578023A1 (en) 2006-03-09
US20150065726A1 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
JP5498524B2 (ja) イソチアゾール誘導体の製造方法
US11001582B2 (en) Solid state forms of Venetoclax and processes for preparation of Venetoclax
ES2561598T3 (es) Derivados de indazol sustituidos con benzodioxinilo
JP5453437B2 (ja) Ｃｂ２受容体を選択的に調節するスルホニル化合物
TW513418B (en) Thiazole derivatives, their production and use
US9815803B2 (en) Process for the preparation of substituted cycloserines
BG65104B1 (bg) Изотиазолови производни, метод за получаването им, фармацевтичен състав и използването им като противоракови средства
JP2025513031A (ja) オキサジアゾール化合物、それを含む医薬組成物及びその使用
HK1111359B (en) Processes for the preparation of isothiazole derivatives
KR20050017776A (ko) 글리메피라이드의 제조방법
ES2250000A1 (es) Procedimiento para la preparacion de ziprasidona.
HK1154580B (en) Benzodioxinyl substituted indazole derivatives

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20130325

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20140325

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20160325

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20170331

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

FPAY Annual fee payment

Payment date: 20180503

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

FPAY Annual fee payment

Payment date: 20190327

Year of fee payment: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20200411

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200411